Page 28 - Read Online

Brettrager et al. Cancer Drug Resist 2019;2:1153-63 I http://dx.doi.org/10.20517/cdr.2019.91 Page 1161

11. Interthal H, Chen HJ, Champoux JJ. Human Tdp1 cleaves a broad spectrum of substrates, including phosphoamide linkages. J Biol
Chem 2005;280:36518-28.
12. Lebedeva NA, Rechkunova NI, El-Khamisy SF, Lavrik OI. Tyrosyl-DNA phosphodiesterase 1 initiates repair of apurinic/apyrimidinic
sites. Biochimie 2012;94:1749-53.
13. Lebedeva NA, Rechkunova NI, Ishchenko AA, Saparbaev M, Lavrik OI. The mechanism of human tyrosyl-DNA phosphodiesterase 1
in the cleavage of AP site and its synthetic analogs. DNA Repair (Amst) 2013;12:1037-42.
14. Lebedeva NA, Rechkunova NI, Lavrik OI. AP-site cleavage activity of tyrosyl-DNA phosphodiesterase 1. FEBS Lett 2011;585:683-6.
15. El-Khamisy SF, Hartsuiker E, Caldecott KW. TDP1 facilitates repair of ionizing radiation-induced DNA single-strand breaks. DNA
Repair (Amst) 2007;6:1485-95.
16. He X, van Waardenburg RC, Babaoglu K, Price AC, Nitiss KC, et al. Mutation of a conserved active site residue converts tyrosyl-
DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison. J Mol Biol 2007;372:1070-81.
17. Inamdar KV, Pouliot JJ, Zhou T, Lees-Miller SP, Rasouli-Nia A, et al. Conversion of phosphoglycolate to phosphate termini on 3’
overhangs of DNA double strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1. J Biol Chem 2002;277:27162-8.
18. Zhou T, Akopiants K, Mohapatra S, Lin PS, Valerie K, et al. Tyrosyl-DNA phosphodiesterase and the repair of 3’-phosphoglycolate-
terminated DNA double-strand breaks. DNA Repair (Amst) 2009;8:901-11.
19. Zhou T, Lee JW, Tatavarthi H, Lupski JR, Valerie K, et al. Deficiency in 3’-phosphoglycolate processing in human cells with a
hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1). Nucleic Acids Res 2005;33:289-97.
20. Murai J, Huang SY, Das BB, Dexheimer TS, Takeda S, et al. Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced
by topoisomerases I and II and base alkylation in vertebrate cells. J Biol Chem 2012;287:12848-57.
21. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res
2012;72:5588-99.
22. Murai J, Marchand C, Shahane SA, Sun H, Huang R, et al. Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory
assay in a quantitative high-throughput screening platform. DNA Repair (Amst) 2014;21:177-82.
23. Prasad R, Horton JK, Dai DP, Wilson SH. Repair pathway for PARP-1 DNA-protein crosslinks. DNA Repair (Amst) 2019;73:71-7.
24. Barthelmes HU, Habermeyer M, Christensen MO, Mielke C, Interthal H, et al. TDP1 overexpression in human cells counteracts DNA
damage mediated by topoisomerases I and II. J Biol Chem 2004;279:55618-25.
25. Nitiss KC, Malik M, He X, White SW, Nitiss JL. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated
DNA damage. Proc Natl Acad Sci U S A 2006;103:8953-8.
26. Gajewski S, Comeaux EQ, Jafari N, Bharatham N, Bashford D, et al. Analysis of the active-site mechanism of tyrosyl-DNA
phosphodiesterase I: a member of the phospholipase D superfamily. J Mol Biol 2012;415:741-58.
27. Hawkins AJ, Subler MA, Akopiants K, Wiley JL, Taylor SM, et al. In vitro complementation of Tdp1 deficiency indicates a
stabilized enzyme-DNA adduct from tyrosyl but not glycolate lesions as a consequence of the SCAN1 mutation. DNA Repair (Amst)
2009;8:654-63.
28. Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J, Leppard JB, et al. SCAN1 mutant Tdp1 accumulates the enzyme - DNA intermediate
and causes camptothecin hypersensitivity. EMBO J 2005;24:2224-33.
29. Takashima H, Boerkoel CF, John J, Saifi GM, Salih MA, et al. Mutation of TDP1, encoding a topoisomerase I-dependent DNA
damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 2002;32:267-72.
30. Cuya SM, Bjornsti MA, van Waardenburg R. DNA topoisomerase-targeting chemotherapeutics: what’s new? Cancer Chemother
Pharmacol 2017;80:1-14.
31. Pouliot JJ, Robertson CA, Nash HA. Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes
Cells 2001;6:677-87.
32. Raymond AC, Rideout MC, Staker B, Hjerrild K, Burgin AB Jr. Analysis of human tyrosyl-DNA phosphodiesterase I catalytic
residues. J Mol Biol 2004;338:895-906.
33. Scott P, Al Kindi A, Al Fahdi A, Al Yarubi N, Bruwer Z, et al. Spinocerebellar ataxia with axonal neuropathy type 1 revisited. J Clin
Neurosci 2019;67:139-44.
34. Dean RA, Fam HK, An J, Choi K, Shimizu Y, et al. Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based
assays. J Biomol Screen 2014;19:1372-82.
35. Duffy S, Fam HK, Wang YK, Styles EB, Kim JH, et al. Overexpression screens identify conserved dosage chromosome instability
genes in yeast and human cancer. Proc Natl Acad Sci U S A 2016;113:9967-76.
36. Comeaux EQ, Cuya SM, Kojima K, Jafari N, Wanzeck KC, et al. Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an
alternative nucleophile that can catalyze substrate cleavage. J Biol Chem 2015;290:6203-14.
37. Cuya SM, Comeaux EQ, Wanzeck K, Yoon KJ, van Waardenburg RC. Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as
cellular toxin. Oncotarget 2016;7:86660-74.
38. Hirano R, Interthal H, Huang C, Nakamura T, Deguchi K, et al. Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1
recessive neomorphic mutation? EMBO J 2007;26:4732-43.
39. Katyal S, el-Khamisy SF, Russell HR, Li Y, Ju L, et al. TDP1 facilitates chromosomal single-strand break repair in neurons and is
neuroprotective in vivo. EMBO J 2007;26:4720-31.
40. Li J, Summerlin M, Nitiss KC, Nitiss JL, Hanakahi LA. TDP1 is required for efficient non-homologous end joining in human cells.
DNA Repair (Amst) 2017;60:40-9.
41. El-Khamisy SF, Saifi GM, Weinfeld M, Johansson F, Helleday T, et al. Defective DNA single-strand break repair in spinocerebellar
ataxia with axonal neuropathy-1. Nature 2005;434:108-13.
42. Davies DR, Interthal H, Champoux JJ, Hol WG. Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA
phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. J Mol Biol 2002;324:917-32.